David Birch, Ph.D.
Scientific Director
Director, Rose-Silverthorne Retinal Degenerations Laboratory
Ph. D., University of California, Santa Barbara, 1978
Office: 214-363-3911 ext.105
Research:
Genetic eye diseases, Macular degeneration, Electrophysiology, Visual function testing
Representative Publications:
Birch DG and Anderson JL. Standardized full-field ERGs: normal values and their variation with age. Arch Ophthal, 1992;110:1571-1576.
Birch DG, Hood DC, Nusinowitz S, and Pepperberg DR. Abnormal activation and inactivation of rod transduction in patients with autosomal dominant retinitis pigmentosa and the pro-23-his mutation. Invest Ophthalmol Vis Sci, 1995; 36:1603-1614.
Birch DG, Anderson JL, and Fish GE. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod degeneration. Ophthalmol, 1999; 106:258-268.
Birch DG. Surrogate electroretinographic markers for assessing therapeutic efficacy in the retina. Exp Rev Mol Diag. 2004; 4: 693-703. PMID: 15347262.
Birch DG, Liang FQ. Age-related macular degeneration: A target for nano-technology derived medicines. International J. Nanomedicine. 2007; 2:1-13. PMID: 17722514.
Hood DC, Lazow MA, Locke KG, Greenstein VC, Birch DG. The transition zone between healthy and diseased retina in patients with retinitis pigmentosa (RP). Invest. Ophthalmol Vis Sci, 2011; 52: 101-108. Aug 20 (Epub ahead of print] PMID: 20720228.
Birch DG, Wen Y, Locke KI, Hood DC. Rod sensitivity, cone sensitivity and photoreceptor layer thickness in retinal degenerative diseases. Invest Ophthalmol Vis Sci, 2011; 52(10): 7141-7. Sept 9, 2011 [Epub ahead of print] PMID: 21810977.
Wen YE, Klein M, Hood DC, Birch DG. Relationships among multifocal electroretinogram amplitude, visual field sensitivity, and SD-OCT receptor layer thickness in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci; Jan 12, 2012 [Epub ahead of print].
Mailing Address:
Dr. David Birch
Retina Foundation of the Southwest
9600 N. Central Expressway, Suite 200
Dallas, TX 75231
USA
Related Articles
COVID-19 Guidelines For Retina Foundation Staff and Visitors Macular Degeneration Stem Cell Clinical Trial Results Allow for Phase II Expansion Children With Amblyopia and Strabismus Take Longer To Complete Answer Forms Introducing the Vision and Neurodevelopment Laboratory Recently@Retina Newsletter March 2023
